Posttranslational modification of proteins by phosphorylation, acetylation and ubiquitination is essential in modulating protein function throughout biology. In particular, phosphorylation is one of the most common regulatory mechanisms in eukaryotes; ~20-30% of all eukaryotic proteins can be phosphorylated by the aggregate activity of >500 kinases 1 . Given the ubiquitous role of phosphorylation in signal transduction, it is not surprising that aberrant phosphorylation either directly causes or is a consequence of many human diseases, such as cancer and neurodegenerative disorders 2 . Recent advances in phosphoproteomic methods have greatly expanded the number of known phosphorylation sites (>170,000) and identified global phosphorylation changes that occur during disease 3-6 . Ultimately, the validation of key phosphorylation events is best conducted at the single-cell level. Recent single-cell studies using phospho-specific mAbs have elucidated how stochastic fluctuations and signaling cross-talk contribute to the overall cellular state 7,8 . Very few commercially available mAbs are suitable for this purpose 7 , and given the steady increase in the number of functionally important phosphorylation sites, there is a pressing need for a rapid, robust method to generate high-quality, renewable, monoclonal phospho-specific detection reagents. Renewable, recombinant mAbs would also provide genetically encoded functional tools for cell biology.
A r t i c l e s Posttranslational modification of proteins by phosphorylation, acetylation and ubiquitination is essential in modulating protein function throughout biology. In particular, phosphorylation is one of the most common regulatory mechanisms in eukaryotes; ~20-30% of all eukaryotic proteins can be phosphorylated by the aggregate activity of >500 kinases 1 . Given the ubiquitous role of phosphorylation in signal transduction, it is not surprising that aberrant phosphorylation either directly causes or is a consequence of many human diseases, such as cancer and neurodegenerative disorders 2 . Recent advances in phosphoproteomic methods have greatly expanded the number of known phosphorylation sites (>170,000) and identified global phosphorylation changes that occur during disease 3-6 . Ultimately, the validation of key phosphorylation events is best conducted at the single-cell level. Recent single-cell studies using phospho-specific mAbs have elucidated how stochastic fluctuations and signaling cross-talk contribute to the overall cellular state 7, 8 . Very few commercially available mAbs are suitable for this purpose 7 , and given the steady increase in the number of functionally important phosphorylation sites, there is a pressing need for a rapid, robust method to generate high-quality, renewable, monoclonal phospho-specific detection reagents. Renewable, recombinant mAbs would also provide genetically encoded functional tools for cell biology.
The state of the art in phospho-specific detection reagents is the generation of antibodies by the immunization of animals 9 . However, this method is often imprecise, low-throughput, expensive, timeconsuming and not typically renewable. Furthermore, the development of phospho-specific mAbs requires additional screening of numerous hybridomas, which is made more challenging by the rarity of phosphospecific mAb clones, estimated to be only 0.1-5% (refs. 10, 11) . Finally, disproportionately more phosphotyrosine (pTyr)-specific mAbs exist than phosphoserine (pSer)-or phosphothreonine (pThr)-specific mAbs. This fact has hindered the study of serine and threonine phosphorylation, which account for 90% and 10% of all phosphorylation sites, respectively, compared with <0.05% for tyrosine 12 . Attempts to generate recombinant phospho-specific mAbs using in vitro selection methods, such as phage display [13] [14] [15] [16] [17] , yeast display 18 and ribosome display 19 , have been even less efficient than immunization methods 18, [20] [21] [22] . Engineered endogenous phosphopeptidebinding domains such as Src-homology-2 (SH2) or forkhead-associated (FHA) domains may provide an alternative to mAbs, but the general utility of these non-antibody scaffolds remains to be demonstrated [23] [24] [25] .
Recently, the combination of immunization and phage display was used to isolate a high-affinity phospho-specific mAb from chickens 21 . Although this approach was successful and led to the first phosphospecific mAb structure, it relies upon a low-throughput and timeconsuming immunization step. We hypothesize that both immunization and in vitro methods for generating phospho-specific mAbs fail to routinely yield high-quality mAbs because most naive mAbs do not possess any detectable affinity for the small, peptide antigens. In light of these difficulties, we envisioned a structure-guided strategy for generating mAbs that employs mAb scaffolds with engineered pockets tailored to a particular motif. This motif-specific anchoring pocket would provide initial antigen-binding affinity and guide the selection of mAbs targeted to epitopes containing the motif (for example, a pSer-or pTyr-containing peptide). These motif residues, known as 'hot spots' , contribute a substantial fraction of the binding energy to a protein-protein interaction 26, 27 .
Here we engineer mAb scaffolds with designed binding pockets for pSer, pThr or pTyr residues and thereby make these residues hot spots in the antigen-mAb interaction. Guided by a natural phosphate-binding motif and knowledge of mAb structure-function, we first identified a parent mAb scaffold in which to install the designed pocket in the complementarity-determining regions (CDRs). We then mutated the scaffold to specifically bind pSer, pThr or pTyr and solved the X-ray Nature-inspired design of motif-specific antibody scaffolds
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Aberrant changes in post-translational modifications (PTMs) such as phosphate groups underlie a majority of human diseases. However, detection and quantification of PTMs for diagnostic or biomarker applications often require PTM-specific monoclonal antibodies (mAbs), which are challenging to generate using traditional antibody-selection methods. Here we outline a general strategy for producing synthetic, PTM-specific mAbs by engineering a motif-specific 'hot spot' into an antibody scaffold. Inspired by a natural phosphate-binding motif, we designed and selected mAb scaffolds with hot spots specific for phosphoserine, phosphothreonine or phosphotyrosine. Crystal structures of the phospho-specific mAbs revealed two distinct modes of phosphoresidue recognition. Our data suggest that each hot spot functions independently of the surrounding scaffold, as phage display antibody libraries using these scaffolds yielded >50 phospho-and target-specific mAbs against 70% of target peptides. Our motif-specific scaffold strategy may provide a general solution for rapid, robust development of anti-PTM mAbs for signaling, diagnostic and therapeutic applications.
crystal structures of the phospho-specific mAb:peptide complexes. In the second step, we constructed two large, diverse, single-chain Fv (scFv) mAb phage display libraries based upon these scaffolds and successfully selected 51 phospho-specific mAbs against seven different pSer-or pThr-containing peptides. These results suggest that the phosphoresidue-binding pocket functions relatively independently of additional structural and functional changes in other CDRs of the mAb.
RESULTS

Design of phospho-specific mAb scaffolds
To design a mAb scaffold with a phosphate-binding motif, we drew upon structural knowledge of how protein domains recognize anions, such as phosphate. The most common anion-binding motif, called a nest, occurs within many different protein super-families, such as ATPases and kinases, and consists of three consecutive residues where multiple main-chain amides form hydrogen bonds with the anion (Supplementary Fig. 1a ) 28 . Starting with this ubiquitous motif, we sought to find an existing mAb scaffold into which we could build a similar short, localized loop. We focused our search on 60 anti-peptide mAb structures and manually inspected the CDRs for the desired nest conformation. We identified a region of CDR H2 within a mouse Fab (PDB ID 1i8i) 29 that adopts the desired conformation owing to a hallmark α L glycine at 54 H (Fig. 1a) . Notably, this mAb uses the H2 loop to bind an acidic residue by means of six loop residues that anchor the peptide (52 H and 52A H ), stabilize the conformation (54 H ), or confer side-chain specificity (53 H , 55 H and 56 H ) ( Fig. 1a and Supplementary  Table 1 ). A larger search of all mAb-antigen structures identified eight mAbs that use this loop to bind an aspartate or glutamate in the antigen (Supplementary Fig. 1b ).
To characterize this class of mAb-antigen interactions, we synthesized the gene encoding a humanized version of the 1i8i Fab and cloned this construct into both a phage display and protein expression vector ( Supplementary Table 2 ). The humanized scaffold, which was expressed at yields >3 mg/l in bacteria, bound the peptide with similar affinity as reported for the mouse Fab 29 . To understand the importance of the Asp-loop (residues 52 H -56 H ) interaction in peptide binding, we performed competition phage enzyme-linked immunosorbent assays (ELISAs) to analyze Fab binding to a panel of peptides. ELISA data confirmed that the Asp8 residue of the antigen is a hot spot for binding, as mutations to Ala, Ser, Thr or Tyr substantially reduced Fab binding (>100-fold less) to the peptide (Fig. 1b) . We reasoned that the carboxylate group of the Asp8 residue might mimic a phosphorylated residue and thus, the mAb may bind peptides with pSer, pThr or possibly pTyr in place of Asp8. ELISA data confirmed the ability of this Fab to bind peptides containing pSer or pThr, albeit with weak affinities (>2,000 nM) ( Fig. 1b and Table 1 ). No mAb binding to the pTyr peptide was observed, probably owing to its large size. Structural analysis of the peptide:Fab complex suggested that steric clashes with several side chains and the main chain of the CDR were likely responsible for the weak affinities.
Therefore, we constructed three antibody phage display libraries to optimize the CDR region for each phosphorylated residue. The sixresidue CDR region (52 H -56 H ) was replaced with six random residues (H2 library) or seven random residues (H2+1 library) to relieve steric clashes with the mAb backbone. The third library design was similar to the H2 library, but fixed Gly or Ser at 53 H and 54 H (GS library). These strategies allowed us to assess the importance of the anchor (52 H and 52A H ) and conformation (54 H ) residues as well as alter the specificity residues (53 H , 55 H and 56 H ). Using standard phage display methods, we then performed four rounds of selection against pSer, pThr and pTyr peptides. Notably, we observed strong enrichment against each of the pSer, pThr and pTyr peptide targets using all three libraries, except for selections with the H2+1 library against pTyr ( Fig. 1c and data not shown).
Characterization of phospho-specific mAb scaffolds
For each phosphopeptide antigen, we isolated single phage clones and sequenced the CDR H2 region for clones that bound to the phosphopeptide by single-point ELISA (data not shown). Selections against the pSer and pThr peptides gave similar sequences and thus were combined into one sequence logo. Sequence logos from the 
npg
A r t i c l e s H2-and GS-library selections against pSer/pThr highlighted the conservation of the key anchoring residue T52A H and conformation residue G54 H in the loop, whereas more diversity was observed in the specificity residues (55 H and 56 H ) ( Fig. 2a) . Notably, in the H2+1 libraries, we observed a strong enrichment for a Pro-Arg insertion in place of G53 H and conservation of G54 H (Fig. 2b) . The G54 H residue occupies a region of the Ramachandran plot in which only glycine is allowed, thus suggesting that this glycine is critical for the conformation [29] [30] [31] . The pTyr mAbs contained a different binding motif from the pSer/pThr mAbs, suggesting that the mode of pTyr recognition differs from that of pSer/pThr recognition (Fig. 2c) .
Next, we analyzed the bacteriophage clones by competition ELISA to identify the best scaffold for each target (pSer, pThr or pTyr) (data not shown). We identified a pSer-specific scaffold (pSAb with sequence ATGGHT), a pSer/pThr-specific scaffold (pSTAb with sequence STPRGST), and a pTyr-specific scaffold (pYAb with sequence VTGGRK). We were unable to isolate a pThr scaffold that did not cross-react with the pSer peptide. To determine the phosphoselectivity of these scaffolds, we analyzed binding to the phosphorylated and unphosphorylated peptides by ELISA and surface plasmon resonance optical biosensors (Supplementary Fig. 2) . Strikingly, we observed high affinity and selectivity for the phosphorylated peptide in all cases ( Fig. 2 and Table 1 ).
Structural analysis of phosphopeptide recognition
To explore the mode of phosphoresidue recognition, we determined the X-ray structure of four Fab:peptide complexes (pSAb:pSer, pSTAb:pSer, pSTAb:pThr and pYAb:pTyr) as well as the unbound pYAb Fab (Supplementary Tables 3 and 4) . We observed strong electron density for the bound peptide in all pSer and pThr structures (Supplementary Fig. 3) . For the pYAb Fab, only one of the two Fab copies in the asymmetric unit was fully occupied by the peptide, likely npg due to the packing arrangement of the Fabs (Supplementary Fig. 3) .
No changes in the positions of the CDRs were observed between the mouse 29 Fig. 4) . For all phosphopeptides, the recognition is achieved through two sectors: the phosphoresidue-binding pocket and a neighboring peptide sequence 'reader' region, which consists primarily of CDRs L3 and H3 (Fig. 3e) . Additionally, all peptide:mAb contacts outside of the phosphoresidue also occur in the parent Fab (Supplementary Fig. 4c ) 29 .
Structures of the peptide:Fab complexes illustrate how CDR H2 specifically recognizes each phosphoresidue (Fig. 3) . For all three scaffolds, mutations found in the parent H2 loop make the main chain more accessible, creating a large electropositive binding pocket (Supplementary Fig. 5 ). The phosphoresidue side chain is almost fully engulfed by the mAb in pSAb (80% buried) and pSTAb (92% buried) and anchored by multiple hydrogen bonds ( Fig. 3a-c, and Supplementary Table 5 ). In pSAb, the pSer residue makes key contacts with specificity residues G53 H , R55 H and T56 H , whereas in pSTAb, the pSer and pThr residues make key contacts with R53 H , G54 H and S55 H . In pSTAb, the insertion of P52B H allows the T52A H anchor to flip out and still contribute a hydrogen bond from the main-chain carbonyl. In stark contrast, pYAb does not use the original designed loop conformation to bind pTyr (Fig. 3d) . A key ionic interaction with K56 H and a hydrophobic interaction with V52 H contribute to the recognition mode.
Notably, the H2 nest pocket is occupied by a water molecule that is stabilized by the free C terminus of the peptide, indicating that pYAb may bind differently to the pTyr residue in longer peptides without this neighboring free carboxylate (Fig. 3d) . Combined, our in vitro characterization and X-ray crystal structures confirmed that we successfully designed mAb scaffolds that use pSer, pThr or pTyr as hot-spot residues.
Generation of target-and phosphospecific mAbs using the pSer and pSer/ pThr scaffolds We hypothesized that an antibody library in which the phosphoresidue-binding pocket was conserved and 'reader' regions were mutated would enable rapid generation of new target-and phospho-specific mAbs. Because every member of the initial library contains a phosphoresidue-binding pocket, each mAb should have a weak initial affinity for the phosphorylated antigen, dramatically enhancing the selection of new mAbs. In proof-of-principle experiments, we targeted antigens containing pSer and pThr, as reagents capable of detecting these modifications are rare. We diversified surface-exposed positions in CDR H2 (50 H , 56 H , 58 H ) outside of the phosphate-binding pocket, CDR H3 (95 H -101 H ), and CDR L3 (91 L -94 L , 96 L ) ( Supplementary Table 6 ).
We chose a set of ten biologically relevant pSer-or pThr-containing epitopes as target antigens ( Table 2) . To increase the stringency of our test, we did not perform counter-selections against the unphosphorylated antigens because we reasoned that the binding pocket could be sufficient for the selection of mAbs that required the phosphorylated residue. We performed three rounds of selection and analyzed single phage clones from the third round of selection by single-point ELISA. For seven targets, we isolated at least one scFv that bound only to the phosphorylated antigen (Table 2 and Fig. 4a) . To test the specificity of the isolated clones, we performed a panel of ELISAs to assay binding of each scFv to each of the ten phosphorylated peptides (Fig. 4b) . The data demonstrates the exquisite target selectivity of most scFv clones, indicating the absence of promiscuous pSer-/pThr-peptide binding scFvs. Western blot analysis confirmed that a sample set of mAbs specifically recognized the corresponding phosphoprotein (Fig. 4c) . Finally, the scFv-Fc fusions exhibited affinities ranging from 42 to a scFv clones that exhibited a more than fivefold higher ELISA signal against phosphorylated peptide compared to unphosphorylated peptide (Fig. 4) . b As determined by competition ELISA with scFv-Fc protein (n = 2-3, error values represent s.d.). Clone ID is shown in parentheses. c Only partial competition was observed at the concentrations of peptide used. Phosphoresidue is shown in bold. Figure 4 Generation of recombinant phospho-specific (PS) mAbs using the pSAb and pSTAb scaffolds. (a) Representative phage ELISAs of one scFv clone selected against each of the nine phosphopeptide targets demonstrates that we selected phospho-specific mAbs to seven out of the ten targets. No hits were observed against P7. To analyze target specificity, we characterized the binding of each scFv-phage to ten different phosphopeptides by phage ELISA (n = 2-3). (b) Heatmap representation of the phage ELISA binding signals for each scFv-phage (horizontal axis) against each of the ten phosphopeptides (vertical axis). Strikingly, most of these scFvs bind only to the phosphopeptide against which they were selected. For each scFv, signals were normalized to the highest overall ELISA signal observed against the ten peptides. The scale goes from zero (black) to one (yellow). (c) scFvs also recognize the phosphorylated protein in western blots. FLAG-tagged target proteins were immunoprecipitated from transiently transfected HEK293T cells.
To verify phospho-specific binding, samples were either dephosphorylated using alkaline phosphatase (AP) or treated with buffer only. Membranes were probed with biotinylated scFv (20 µg/ml) overnight and bound scFv was detected using NeutrAvidin-HRP. Total levels of target protein were monitored using anti-FLAG-HRP.
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A r t i c l e s 5,000 nM ( Table 2) , which matches or exceeds previous reports of phospho-specific mAb affinities 18, 21 .
DISCUSSION
Here we describe a recombinant mAb-generation method that entails the design of a motif-specific (for example, pSer, pThr or pTyr) mAb scaffold followed by structure-informed mutagenesis of the scaffold to generate mAbs against a panel of phosphopeptide antigens. The high success rate of our strategy (phospho-specific mAbs against seven of ten targets), which does not employ counter-selections against the unphosphorylated epitope, demonstrates how the motif-specific pocket greatly improves the selection process, as even past antibody libraries generated from immunized animals required stringent counterselections to enrich for phospho-specific mAbs 21, 22 . In the case of pSAb and pSTAb, the pocket contains a hallmark α L glycine at 54 H that contributes to the main-chain conformation of CDR H2. There is a very high frequency of occurrence for this H2 conformation in mAbs (~12% of all H2 conformations 31 ), and multiple mAb structures with anionic molecules (for example, aspartate, glutamate or sulfate) bound at this site (Supplementary Fig. 1) .
While our studies were in progress, the structure of a chicken scFv, which was generated from an immunized phage display library, was reported. The antibody was found to have a similar H2 conformation that bound the pThr-containing phosphopeptide 21 . Notably, a structural comparison of this chicken scFv with our mAbs reveals that the phosphoresidue binds to the same H2 loop conformation albeit with a different hydrogen bonding pattern (Supplementary Fig. 6 ). This striking similarity suggests there may be a germline-encoded, anion-binding pocket capable of binding phosphate or sulfate groups. In fact, previous work on mAbs that bind phospholipids suggested a 'phosphate-binding subsite' that conferred recognition of only the phosphorylated or sulfated forms of multiple lipids and haptens 32 . Furthermore, anion-binding, pocket-containing mAbs may provide a protective role in the recognition of phosphorylated or sulfated antigens, such as lipid A in Gram-negative bacteria 32 , or conversely, a more sinister role in autoimmune diseases, such as antiphospholipid syndrome 33 . Future crystallographic studies of these mAb:antigen complexes will illuminate this intriguing possibility.
Interestingly, the main-chain dominated mode of pSer/pThr recognition is completely different from most endogenous pSer/ pThr-binding domains such as SH2, 14-3-3 and FHA, which predominantly use side chains to bind the phosphoresidue 34 (Fig. 3  and Supplementary Fig. 7) . Only the WW domain sometimes uses two main-chain amides to bind a phosphate. In fact, our pSer/pThr scaffolds bind more efficiently to the phosphoresidue than naturally occurring domains by burying a larger surface area and contributing more hydrogen bonds ( Supplementary Table 5 ). It was recently suggested that these endogenous phosphoresidue-binding and other PTM-binding domains have evolved to bind shorter epitopes with moderate affinities to support the dynamic nature of signal transduction pathways, which potentially limits the range of epitopes they can bind [34] [35] [36] . Additionally, our designed phosphospecific pockets appear to function independently of the other CDRs as we could diversify those CDRs to target highly diverse phosphopeptides (Fig. 4) .
Surprisingly, pYAb uses a completely different motif to recognize pTyr. It is notable that we achieved highly specific recognition of pTyr, despite not burying most of the pTyr phenyl ring (Figs. 2c  and 3d) . However, we have yet to determine how the presence of the free carboxylate, which stabilizes a water molecule in the nest, contributes to the binding affinity. We are currently developing new scaffolds in which most of the pTyr residue is buried and bound in a more nest-like region to boost the ligand efficiency and affinity.
Our bacteriophage-derived phospho-specific mAb platform, which can be automated, rapidly generates mAbs within 2 weeks as opposed to more than several months required for hybridoma methods. In stark contrast to traditional monoclonal or polyclonal phospho-specific antibodies, our recombinant phospho-specific mAbs use a single framework that permits high-level bacterial expression (>3 mg/l) and mammalian expression (~0.5-5 µg/ml media) in a renewable format. The use of a single framework greatly simplifies mutagenesis protocols (for example, affinity maturation), sequence-function analysis and conversion to other mAb formats (for example, IgG) 17 . Finally, we hypothesize that this motif-specific scaffold method should be generalizable to targeting virtually any antigen with a defined motif. As many other PTM-binding motifs exist in nature, these motifs may be similarly designed into mAbs to generate high-affinity monoclonal reagents capable of detecting other PTMs. Ultimately, the rapid in vitro generation of monoclonal anti-PTM antibodies will greatly enhance the study of PTMs throughout biology.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. PDB: X-ray coordinates for pSAb:pSer (4JFZ), pSTAb:pSer (4JG0), pSTAb:pThr (4JG1), pYAb:pTyr (4JFX) and pYAb (4JFY).
